Genelabs Technologies, Inc.

Smithkline Beecham Corporation

Jesse Daniel Keicher

Christopher Don Roberts

Natalia Dyatkina

Mark Douglas Velligan

Mikail Hakan Gezginci

Christoher Don Roberts

Disclosed are methods for treating hepatitis C viral infections using deaza-purine compounds of Formula I: wherein W, W, W, Y, R, Z, Y' and R are as defined herein.

Nucleoside derivatives for treating hepatitis C virus infection

Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus.

Tricyclic-nucleoside prodrugs for treating viral infections

Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus. 

Tricyclic-nucleoside compounds for treating viral infections

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein W, W, W, Y, R, Z, Y' and R are as defined herein.

Nucleoside derivatives for treating Hepatitis C virus infection

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

5-nitro-nucleoside compounds for treating viral infections

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, T, Y, W, Wand Ware as defined herein.

Nucleoside compounds for treating viral infections

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, each of R, Y, W, Wand Ware as defined herein.

Disclosed are methods and intermediates for the preparation of 7-(2'-R-substituted-&#x3b2;-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds. These compounds are useful in treating viral infections caused by afamily virus, such as hepatitis C virus. Such 7-(2&#x2032;-substituted-&#x3b2;-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds are represented by Formula I as follows: wherein, each of R, R, and Rare as defined herein.

[object Object]

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, Y, W, Wand Ware as defined herein.

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, R, Y, W, Wand Ware as defined herein.

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, each of R, Y, W, Wand Wis as defined herein.

Disclosed are 6-hydroxyamino- or a 6-alkoxyamino-7-deazapurine-ribofuranose derivatives, salts, pharmaceutical compositions, and methods of use thereof for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

This invention provides novel compounds possessing antibacterial and/or antifungal and/or antitumor activity. Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.

Growing community of inventors

San Carlos, CA, United States of America

Jesse Daniel Keicher